Healthcare
180 Life Sciences Corp. Enters the iGaming Industry with Blockchain-Enabled Platform
Leveraging blockchain and cryptocurrency technology, 180 Life Sciences aims to revolutionize the online casino market In a strategic move that...
Bright Minds Biosciences Soars 1,400% in Unprecedented Stock Surge
In an unexpected and dramatic move, Bright Minds Biosciences (DRUG) saw its stock skyrocket by an astonishing 1,400% yesterday, despite...
Larimar Therapeutics: Targeting the Root Cause of Friedreich’s Ataxia with Nomlabofusp
Biotech company poised to lead FA treatment with innovative protein replacement therapy Larimar Therapeutics (LRMR) has emerged as a promising...
Perspective Therapeutics Expands Radiopharmaceutical Production with New Facility in New Jersey
State-of-the-art facility supports advanced cancer treatment applications, accelerating product distribution Perspective Therapeutics (CATX), a leading radiopharmaceutical company, has announced the...
CATX Showcases Breakthroughs in Radiopharmaceutical Development at Oppenheimer Summit
Targeted radiopharmaceuticals promising multiple catalysts and clinical advancements heading into 2024 CATX (CATX), a company pioneering targeted radiopharmaceutical therapies, provided...
OnKure Positioned for Success with PI3Kα Inhibitor OKI-219 in Breast Cancer
Targeting H1047R Mutations for Improved Efficacy and Reduced Toxicity in an Expanding Market OnKure Therapeutics (OKUR) is making waves in...
VKTX Set to Showcase Promising Higher-Dose Data for Oral VK2735 at ObesityWeek
Potential Upside in Obesity Treatment as Higher Dose Efficacy Data Expected to Boost Competitive Profile Viking Therapeutics (VKTX) is gearing...
Emerging Therapeutic Developments: TYRA, RVMD, IDYA, and More Poised for Key Data Releases
Major trials signal potential advancements in cancer treatment and rare disease therapies Biotech companies are preparing for significant milestones as...
Ligand Pharmaceuticals: A Diversified Biotech Powerhouse Poised for Growth
With Over 70 Royalty Streams, Ligand’s Unique Business Model Offers Compelling Opportunities for Investors Ligand Pharmaceuticals (LGND) is rapidly emerging...
Larimar Therapeutics Poised for Growth with Nomlabofusp: Target Price Set at $22
FDA START Program and Strong Financials Offer Promising Outlook for Friedreich’s Ataxia Treatment Larimar Therapeutics (LRMR) is making waves in...
